Cocrystal Pharma Inc (COCP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cocrystal Pharma Inc (COCP) has a cash flow conversion efficiency ratio of -0.569x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.34 Million) by net assets ($4.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cocrystal Pharma Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Cocrystal Pharma Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Cocrystal Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cocrystal Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cocrystal Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sarama Resource
V:SWA
|
0.426x |
|
Sunlands Technology Group
NYSE:STG
|
0.151x |
|
Chibougamau Independent Mines Inc
V:CBG
|
0.012x |
|
TCTM Kids IT Education Inc.
NASDAQ:VSA
|
N/A |
|
Simris Alg AB (publ)
ST:SIMRIS-B
|
-0.723x |
|
TAO Synergies Inc.
NASDAQ:TAOX
|
-0.072x |
|
AroCell AB
ST:AROC
|
-0.010x |
|
Imexhs Ltd
AU:IME
|
-0.103x |
Annual Cash Flow Conversion Efficiency for Cocrystal Pharma Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Cocrystal Pharma Inc from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Cocrystal Pharma Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.33 Million | $-8.19 Million | -1.294x | +25.25% |
| 2024-12-31 | $9.52 Million | $-16.48 Million | -1.731x | -211.42% |
| 2023-12-31 | $26.38 Million | $-14.67 Million | -0.556x | -2.61% |
| 2022-12-31 | $39.57 Million | $-21.43 Million | -0.542x | -230.30% |
| 2021-12-31 | $77.55 Million | $-12.72 Million | -0.164x | +12.40% |
| 2020-12-31 | $52.51 Million | $-9.83 Million | -0.187x | -207.94% |
| 2019-12-31 | $25.71 Million | $-1.56 Million | -0.061x | +50.94% |
| 2018-12-31 | $66.89 Million | $-8.29 Million | -0.124x | -89.24% |
| 2017-12-31 | $105.40 Million | $-6.90 Million | -0.065x | +54.27% |
| 2016-12-31 | $102.32 Million | $-14.65 Million | -0.143x | -132.67% |
| 2015-12-31 | $167.59 Million | $-10.32 Million | -0.062x | +93.19% |
| 2014-12-31 | $6.65 Million | $-6.01 Million | -0.903x | -219.17% |
| 2013-12-31 | $-6.03 Million | $-4.57 Million | 0.758x | +84.47% |
| 2012-12-31 | $-3.58 Million | $-1.47 Million | 0.411x | +170.34% |
| 2011-12-31 | $-2.77 Million | $-420.95K | 0.152x | +105.45% |
| 2010-12-31 | $6.93K | $-19.34K | -2.791x | -506.59% |
| 2009-12-31 | $54.54K | $-25.10K | -0.460x | -30.68% |
| 2008-12-31 | $95.34K | $-33.58K | -0.352x | -51.65% |
| 2007-12-31 | $147.13K | $-34.17K | -0.232x | -- |
About Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more